Fujian Aonong Biological Technology Group Incorporation Limited
SSE:603363.SS
3.77 (CNY) • At close June 6, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 8,762.673 | 19,457.641 | 21,613.04 | 18,038.16 | 11,517.166 | 5,788.08 | 5,761.892 | 4,902.66 | 4,978.471 | 4,012.709 | 4,184.443 | 2,953.81 |
| Cost of Revenue
| 8,366.781 | 20,766.889 | 20,664.799 | 17,780.505 | 9,529.061 | 5,050.516 | 4,972.732 | 3,978.17 | 4,107.292 | 3,260.128 | 3,508.782 | 2,495.052 |
| Gross Profit
| 395.892 | -1,309.247 | 948.241 | 257.656 | 1,988.104 | 737.564 | 789.16 | 924.49 | 871.179 | 752.581 | 675.661 | 458.758 |
| Gross Profit Ratio
| 0.045 | -0.067 | 0.044 | 0.014 | 0.173 | 0.127 | 0.137 | 0.189 | 0.175 | 0.188 | 0.161 | 0.155 |
| Reseach & Development Expenses
| 0 | 148.859 | 161.673 | 113.877 | 65.36 | 72.851 | 109.733 | 107.346 | 111.293 | 86.358 | 86.03 | 0 |
| General & Administrative Expenses
| 0 | 142.268 | 168.078 | 166.54 | 143.177 | 60.991 | 52.534 | 51.128 | 45.549 | 92.585 | 34.019 | 126.034 |
| Selling & Marketing Expenses
| 0 | 360.159 | 412.696 | 338.12 | 246.758 | 253.451 | 402.612 | 451.32 | 464.721 | 413.556 | 445.207 | 286.471 |
| SG&A
| 251.444 | 1,117.128 | 580.774 | 504.66 | 389.935 | 314.442 | 455.146 | 502.449 | 510.27 | 506.141 | 479.226 | 412.505 |
| Other Expenses
| -327.445 | 1,074.908 | 462.415 | 437.903 | 275.321 | 130.795 | -1.709 | -0.156 | 7.205 | 4.66 | 12.455 | 0.039 |
| Operating Expenses
| -21.531 | 2,340.895 | 1,204.862 | 1,056.44 | 730.616 | 518.087 | 665.114 | 721.411 | 724.04 | 673.757 | 624.307 | 412.526 |
| Operating Income
| 417.423 | -2,665.752 | -386.665 | -886.831 | 965.622 | 208.744 | 21.59 | 148.918 | 115.146 | 51.565 | 32.438 | 35.542 |
| Operating Income Ratio
| 0.048 | -0.137 | -0.018 | -0.049 | 0.084 | 0.036 | 0.004 | 0.03 | 0.023 | 0.013 | 0.008 | 0.012 |
| Total Other Income Expenses Net
| -332.928 | -995.625 | -898.878 | -14.92 | 4.897 | -131.003 | -1.709 | -29.032 | -20.923 | 3.283 | 12.455 | 0.032 |
| Income Before Tax
| 84.495 | -3,661.376 | -1,295.035 | -1,821.577 | 970.519 | 77.741 | 19.881 | 148.762 | 120.503 | 54.848 | 44.893 | 35.573 |
| Income Before Tax Ratio
| 0.01 | -0.188 | -0.06 | -0.101 | 0.084 | 0.013 | 0.003 | 0.03 | 0.024 | 0.014 | 0.011 | 0.012 |
| Income Tax Expense
| 21.403 | 87.053 | -68.085 | 29.343 | -23.086 | -22.615 | 9.638 | 26.686 | 12.153 | 16.159 | 5.672 | 12.034 |
| Net Income
| 579.345 | -3,650.822 | -1,226.951 | -1,850.92 | 993.605 | 100.356 | 30.126 | 108.119 | 91.376 | 33.777 | 42.745 | 24.991 |
| Net Income Ratio
| 0.066 | -0.188 | -0.057 | -0.103 | 0.086 | 0.017 | 0.005 | 0.022 | 0.018 | 0.008 | 0.01 | 0.008 |
| EPS
| 0.67 | -4.21 | -1.58 | -3.36 | 1.65 | 0.18 | 0.055 | 0.22 | 0.19 | 0.077 | 0.097 | 0.057 |
| EPS Diluted
| 0.67 | -4.21 | -1.58 | -3.36 | 1.58 | 0.18 | 0.054 | 0.22 | 0.19 | 0.077 | 0.097 | 0.057 |
| EBITDA
| 1,567.993 | -1,344.717 | 500.424 | -269.95 | 1,474.887 | 323.933 | 193.461 | 249.166 | 161.573 | 84.787 | 62.912 | 50.294 |
| EBITDA Ratio
| 0.179 | -0.069 | 0.023 | -0.015 | 0.128 | 0.056 | 0.034 | 0.051 | 0.032 | 0.021 | 0.015 | 0.017 |